2 min read
Operationalizing Adaptive Design for FDA's One-Trial Era
Operationalizing Adaptive Design for FDA's One-Trial Era
October 20, 2026 : 11:00 AM ET
On February 18, 2026, the FDA...
AI is changing clinical development, but speed alone isn't enough. In a regulated industry, every output still has to be accurate, traceable, and ready to withstand regulatory scrutiny.
That's the central theme of Veristat’s Kyle McBride's recent conversation on the Life Sciences Today podcast with Healthcare IT Today.
Kyle discusses why successful AI adoption in biostatistics depends on more than large language models or automation. It requires validated systems, expert oversight, and workflows built specifically for clinical development.
Listen to the full episode if you're interested in the future of AI in clinical research.
The Discussion Covers:
- Why regulated AI demands a different approach than consumer AI
- How automation can help accelerate submission-ready statistical deliverables
- The importance of maintaining quality and confidence as timelines shrink
- How InStat™ by Veristat™ combines automation with biostatistical expertise to modernize analysis workflows
Get the Latest News
Categories
- Regulatory Consulting (141)
- Regulatory Submissions (135)
- Clinical Trial Regulations (123)
- COVID-19 (46)
- Strategic Consulting (39)
- Clinical Trials (35)
- Life At Veristat (20)
- Oncology (18)
- Events (16)
- Success Stories (13)
- Clinical Operations/Monitoring (12)
- Project Management (11)
- Decentralized Trials/Virtual Trials (9)
- Full-Service (9)
- Medical Writing (9)
- CMC (6)
- Data Management (5)
- Marketing Applications (5)
- Adaptive Design (4)
- Neurology/CNS (4)
- Statistics and Programming (4)
- Biologics (3)
- Cell Gene and RNA (3)
- Biometrics (2)
- Natural History (2)
- Psychedelics (2)
- Rare Diseases (2)
- AI (1)
- Global Markets (1)
- Hematology (1)
- InStat (1)
- Medical Affairs (1)
2 min read
Meet Veristat at the iC³ Life Science and Healthcare Innovation Summit
Aug 26, 2026 Veristat Events